As of 2024-12-14, the EV/EBITDA ratio of TherapeuticsMD Inc (TXMD) is -4.43. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TXMD's latest enterprise value is 9.02 mil USD. TXMD's TTM EBITDA according to its financial statements is -2.04 mil USD. Dividing these 2 quantities gives us the above TXMD EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.7x - 8.7x | 7.1x |
| Forward P/E multiples | 4.3x - 8.3x | 5.7x |
| Fair Price | (0.39) - (1.03) | (0.69) |
| Upside | -132.2% - -184.1% | -156.8% |
| Date | EV/EBITDA |
| 2024-12-11 | -4.60 |
| 2024-12-10 | -4.65 |
| 2024-12-09 | -4.88 |
| 2024-12-06 | -4.48 |
| 2024-12-05 | -4.65 |
| 2024-12-04 | -4.99 |
| 2024-12-03 | -5.14 |
| 2024-12-02 | -5.27 |
| 2024-11-29 | -5.56 |
| 2024-11-27 | -5.50 |
| 2024-11-26 | -5.44 |
| 2024-11-25 | -5.39 |
| 2024-11-22 | -5.27 |
| 2024-11-21 | -5.05 |
| 2024-11-20 | -5.10 |
| 2024-11-19 | -4.88 |
| 2024-11-18 | -4.82 |
| 2024-11-15 | -5.44 |
| 2024-11-14 | -5.78 |
| 2024-11-13 | -5.99 |
| 2024-11-12 | -6.01 |
| 2024-11-11 | -6.12 |
| 2024-11-08 | -6.12 |
| 2024-11-07 | -6.12 |
| 2024-11-06 | -6.24 |
| 2024-11-05 | -6.24 |
| 2024-11-04 | -6.29 |
| 2024-11-01 | -6.29 |
| 2024-10-31 | -6.29 |
| 2024-10-30 | -6.29 |
| 2024-10-29 | -6.41 |
| 2024-10-28 | -6.38 |
| 2024-10-25 | -6.52 |
| 2024-10-24 | -6.46 |
| 2024-10-23 | -6.43 |
| 2024-10-22 | -6.46 |
| 2024-10-21 | -6.43 |
| 2024-10-18 | -6.58 |
| 2024-10-17 | -6.46 |
| 2024-10-16 | -6.46 |
| 2024-10-15 | -6.16 |
| 2024-10-14 | -6.12 |
| 2024-10-11 | -6.46 |
| 2024-10-10 | -6.46 |
| 2024-10-09 | -6.46 |
| 2024-10-08 | -6.69 |
| 2024-10-07 | -6.92 |
| 2024-10-04 | -6.82 |
| 2024-10-03 | -6.58 |
| 2024-10-02 | -6.86 |